Showing results (841-850 of 988) with videos related to

Sort By:
Pageof 99
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 29, 2008
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology GroupMichael C Heinrich, Kouros Owzar, Christopher L Corless, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2025
Basic Science and PathogenesisGrace C George, Sarah A Keller, W Ryan Powell, et al.
The Oncologist|July 4, 2025
Long-term efficacy and safety of pexidartinib in patients with tenosynovial giant cell tumor: final results of the ENLIVEN studyAndrew J Wagner, William D Tap, Sebastian Bauer, et al.
Air Quality, Atmosphere, & Health|November 22, 2016
A class of non-linear exposure-response models suitable for health impact assessment applicable to large cohort studies of ambient air pollutionMasoud M Nasari, Mieczysław Szyszkowicz, Hong Chen, et al.
Annals of the Rheumatic Diseases|February 26, 2011
Evidence to support IL-13 as a risk locus for psoriatic arthritis but not psoriasis vulgarisJohn Bowes, Steve Eyre, Edward Flynn, et al.
NPJ Precision Oncology|January 24, 2025
Dual anti-CTLA-4 and anti-PD-1 blockade in metastatic basal cell carcinomaSandip P Patel, Eleanor Cano-Linson, Young Kwang Chae, et al.
Cancer|June 8, 2019
Overall survival and histology-specific subgroup analyses from a phase 3, randomized controlled study of trabectedin or dacarbazine in patients with advanced liposarcoma or leiomyosarcomaShreyaskumar Patel, Margaret von Mehren, Damon R Reed, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2009
Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancerMary-Ellen Taplin, Meredith M Regan, Yoo-Joung Ko, et al.
Oncotarget|March 19, 2015
Multilevel-analysis identify a cis-expression quantitative trait locus associated with risk of renal cell carcinomaXiang Shu, Mark P Purdue, Yuanqing Ye, et al.
Cancer Communications (London, England)|May 22, 2025
A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: durable responses and delayed pseudoprogression in small cell carcinoma of the ovary, hypercalcemic type cohortYoung Kwang Chae, Megan Othus, Sandip Pravin Patel, et al.
Pageof 99